1391602-69-9

Basic information

• Product Name: N-(1-benzyl-4-hydroxymethyl-piperidin-4-yl)-2-chloro-acetamide
• Synonyms: N-(1-benzyl-4-hydroxymethyl-piperidin-4-yl)-2-chloro-acetamide
• CAS NO: 1391602-69-9
• Molecular Weight: 296.797
• Mol File: 1391602-69-9.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: N-(1-benzyl-4-hydroxymethyl-piperidin-4-yl)-2-chloro-acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(1-benzyl-4-hydroxymethyl-piperidin-4-yl)-2-chloro-acetamide(1391602-69-9)
• EPA Substance Registry System: N-(1-benzyl-4-hydroxymethyl-piperidin-4-yl)-2-chloro-acetamide(1391602-69-9)

Safety Data

• Hazardous Substances Data: 1391602-69-9(Hazardous Substances Data)

Upstream product

• 312928-52-2 (4-amino-1-benzyl-piperidin-4-yl)-methanol 
• 79-04-9 chloroacetyl chloride 
• 28936-94-9 8-benzyl-1,3,8-triaza-spiro[4.5]decane-2,4-dione 
• 39143-25-4 1-benzyl-4-amino-4-piperidinecarboxylic acid 
• 3612-20-2 1-phenylmethyl-4-piperidone 

Downstream Products

• 1169699-61-9 9-benzyl-4-oxa-1,9-diaza-spiro[5.5]undecan-2-one 
• 1160247-03-9 2-oxo-4-oxa-1,9-diaza-spiro[5.5]undecane-9-carboxylic acid tert-butyl ester 
• 1391602-71-3 1-methyl-4-oxa-1,9-diaza-spiro[5,5]undecan-2-one hydrochloride 

Relevant articles and documents

Spirocyclic derivatives

The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease, disorder or condition ameliorated by inhibition of a dopamine transporter); and methods of treating patients with such compounds; wherein R1, R2, R3, R4, R5, R6, R9, R10, Q, X, Y, Z, A, L, B, m, n and p are as defined herein.

SUBSTITUTED PYRIDINYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS

The invention relates to new substituted pyridinyl-pyrimidines of formula 1 wherein ring A is a five-membered saturated or unsaturated carbocyclic ring which optionally comprises one, two or three heteroatoms each independently from each other selected from the group N, S and O, wherein R1, R2, R4, R3, R5 and R6 are defined as in claim 1 and wherein ring A is further optionally substituted by one or two further substituents and the pharmaceutically acceptable salts, diastereomers, enantiomers, racemates, hydrates and solvates of the aforementioned compounds.